DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Decision Resources Group (DRG) and the Centre for Innovation in Regulatory Science (CIRS) are proud to present a new report on pharmaceutical benchmarks and trends:
2020 CIRS Regulatory and Access Factbook
Navigate regulatory and access hurdles with actionable insight

You can rely on the Centre for Innovation in Regulatory Science's (CIRS) 20+ years of experience to provide the details that can inform your regulatory and access decisions.

  • integrates regulatory observations from mature and emerging markets, describing important HTA benchmarks, illustrating access to new medicines
  • includes comparative analyses of regulatory authorisation times, lag time, impact of expedited pathways, therapeutic areas across 6 mature agencies and regulatory consortia
  • gives regulatory insight on activities of 18 emerging markets addressing yearly authorisation time changes, use of verification & abridged reviews looking at the impact of reliance pathways and more
  • gives practical examples of how regulatory intelligence maximises the impact on regulatory policy and advocacy
  • shares learnings from HTA and regulatory interactions and much more...

The CIRS Factbook unified approach gives, an independent but connected source of practical insight not seen in other annuals which can immediately be operationalised in your daily planning and long-term strategies.

Get a detailed view of your regulatory and market access landscape:
Comparative analyses of regulatory authorisation times, lag times, impact of expedited pathways, therapeutic areas and more across 6 mature agencies and regulatory consortia.

Insights into the regulatory activities of 18 emerging markets addressing yearly authorisation time changes, use of verification and abridged reviews, impact of reliance pathways and more.

HTA outcomes and timelines for Australia, Canada and Europe, synchronisation of recommendations, impact of FDA breakthrough designation and more. Learnings from HTA and regulatory interactions.

Practical examples of how regulatory intelligence maximises policy and advocacy.

INDISPENSABLE PHARMACEUTICAL BENCHMARKS AND TRENDS

SEE THE 2020 FACTBOOK CONTENTS HERE.